Big Pharma loves billion-dollar M&A headlines, but where are they when early-stage innovation needs a lifeline?  

Why pharma rarely engages before Phase 2, and whether that can change 

What can early-stage biotechs do to attract big pharma interest? 

Real-world case studies of early partnerships that defies the trend